




# PHARMACEUTICAL 2021

ImmunoGen Inc.  
Rank 263 of 402





# PHARMACEUTICAL 2021

ImmunoGen Inc.  
Rank 263 of 402



The relative strengths and weaknesses of ImmunoGen Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ImmunoGen Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 48% points. The greatest weakness of ImmunoGen Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 45% points.

The company's Economic Capital Ratio, given in the ranking table, is 35%, being 12% points below the market average of 47%.

| Input Variable                              | Value in 1000 USD |
|---|-------------------|
| Assets, Current                             | 324,254           |
| Cost of Goods Sold                          | 0                 |
| Intangible Assets                           | 0                 |
| Liabilities, Current                        | 122,323           |
| Liabilities, Non-Current                    | 102,097           |
| Other Assets                                | 25,058            |
| Other Compr. Net Income                     | 0                 |
| Other Expenses                              | 24,689            |
| Other Liabilities                           | 41,082            |
| Other Net Income                            | 1,210             |
| Other Revenues                              | 132,299           |
| Property and Equipment                      | 5,760             |
| Research and Development                    | 114,592           |
| Selling, General and Administrative Expense | 38,600            |

| Output Variable          | Value in 1000 USD |
|--------------------------|-------------------|
| Assets                   | 355,072           |
| Liabilities              | 265,502           |
| Expenses                 | 177,881           |
| Revenues                 | 132,299           |
| Stockholders Equity      | 89,570            |
| Net Income               | -44,372           |
| Comprehensive Net Income | -44,372           |
| Economic Capital Ratio   | 35%               |